Based on my limited knowledge on this topic, I think as long as a trial is not using patented assays or technology belonging to the university, the company does not owe them any royalties if and when the product is marketed. Therefore in this case, I do not think ONCS would owe UCSF anything besides gratitude if and when this procedure becomes approved for commercialization.
News 
Market Data 
Discover 
AI
